Traduction de «acquisition of privately-held » (Néerlandais → Français) :

Maker of Emergen-C®, #1 U.S. Vitamin C Brand, Expands Pfizer’s Vitamin and Dietary Supplement Business NEW YORK, N.Y., February 27 - Pfizer Inc (NYSE:PFE) today announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.
- - - Maker of Emergen-C®, #1 U.S. Vitamin C Brand, Expands Pfizer’s Vitamin and Dietary Supplement Business NEW YORK, N.Y., February 27 - Pfizer Inc (NYSE:PFE) today announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.

Sandoz – Oriel Therapeutics On June 1, Sandoz completed the acquisition of the privately held US based Oriel Therapeutics Inc., to broaden its portfolio of projects in the field of respiratory drugs for a total purchase consideration of USD 332 million.
Sandoz – Oriel Therapeutics Le 1 er juin, Sandoz a terminé l’acquisition d’Oriel Therapeutics Inc., une entreprise américaine non cotée, afin d’élargir son portefeuille de projets dans le domaine des médicaments respiratoires. Le prix d’achat s’élève à USD 332 millions.

Pharmaceuticals – Corthera On February 3, Novartis completed the acquisition of the privately held US based Corthera Inc., gaining worldwide rights to Relaxin for the treatment of acute decompensated heart failure and assumed full responsibility for development and commercialization for a total purchase consideration of USD 327 million.
Pharmaceuticals – Corthera Le 3 février, Novartis a achevé l’acquisition de Corthera Inc., une entreprise américaine non cotée, pour un prix total d’USD 327 millions.

On June 1, Sandoz completed the acquisition of Oriel Therapeutics, a privately held US pharmaceuticals company.
Le 1 er juin, Sandoz a achevé l’acquisition d’Oriel Therapeutics, une société américaine non cotée.

Sandoz – Oriel Therapeutics On June 1, Sandoz completed the acquisition of the privately held US based Oriel Therapeutics Inc., to broaden its portfolio of projects in the field of respiratory drugs for a total purchase consideration of USD 329 million.
Sandoz – Oriel Therapeutics Le 1 er juin, Sandoz a terminé l’acquisition d’Oriel Therapeutics Inc., une entreprise américaine non cotée, afin d’élargir son portefeuille de projets dans le domaine des médicaments respiratoires. Le prix d’achat s’élève à USD 329 millions.

Pharmaceuticals – Protez On June 4, Novartis agreed to acquire Protez Pharmaceuticals, a privately held US biopharmaceuticals company, gaining access to PTZ601, a broad-spectrum antibiotic in Phase II development against potentially fatal drug-resistant bacterial infections.
Pharmaceuticals – Protez Le 4 juin, Novartis a convenu d’acquérir Protez Pharmaceuticals, une société américaine de biotechnologie en mains privées. Cet accord a permis à Novartis d’accéder à PTZ-601, un antibiotique à large spectre en phase II de développement pour traiter des infections bactériennes potentiellement fatales qui résistent aux médicaments.

The acquisition price for the 90.3% interest not previously held is approximately CHF 939 million (USD 888 million) excluding USD 26 million of cash held by Speedel as of the July acquisition date of majority control.
Le prix d’acquisition des 90,3% que Novartis ne détenait pas encore est approximativement de CHF 939 millions (USD 888 millions), hors USD 26 millions de liquidités que Speedel détenait à la date d’acquisition de la majorité de contrôle en juillet.

The acquisition price for the 90.3% interest not previously held was approximately CHF 939 million (USD 888 million) excluding USD 26 million of cash held by Speedel as of the July acquisition date of majority control.
Le prix d’acquisition des 90,3% que Novartis ne détenait pas encore était approximativement de CHF 939 millions (USD 888 millions), hors USD 26 millions de liquidités que Speedel détenait à la date d’acquisition de la majorité de contrôle en juillet.